FDA Launches Nonprescription Drug Stakeholder Engagement Plan Targeting

A structured FDA engagement plan is now reshaping the pathway for prescription-to-nonprescription switches, with direct implications for labeling strategy, application dossier construction, and manufacturing controls at facilities holding or pursuing OTC-eligible drug approvals. The agency's multi-phase initiative signals a deliberate expansion of the nonprescription drug market through the formal drug application process, not regulatory shortcuts.

The plan comprises four sequential components: a public request for information issued December 2, 2025 (90 FR 55316), a December 2025 public meeting on epinephrine accessibility in the nonprescription setting, an April 23, 2026 public meeting on access strategies and Rx-to-OTC switch criteria, and a forthcoming pilot program expected to be announced within Calendar Year 2026. Each phase has generated a public docket; FDA reopened the December 2025 docket following the April meeting to capture additional stakeholder input on specific topics raised.

For regulatory affairs leads, the April 2026 meeting is the most operationally dense. Participants addressed the evidentiary standards required to demonstrate safety and effectiveness in the nonprescription setting, criteria for identifying switch-ready candidates, and the mechanism of an additional condition for nonprescription use (ACNU) as an access-enabling tool. These discussions will likely inform forthcoming draft guidance, which is listed as the fourth element of the engagement plan and will carry a public comment period.

Manufacturing and QA teams should read the ACNU mechanism carefully. If conditions attach to nonprescription availability, labeling, packaging configuration, and consumer-directed instructions for use become GMP-relevant variables, not just marketing decisions. Process validation packages and 21 CFR Part 211 documentation may need to account for consumer-use scenarios that differ materially from supervised clinical or pharmacy settings.

The pilot program, once announced, is expected to provide structured development support for nonprescription candidates, including switches. Application holders evaluating their portfolios for OTC candidacy should monitor the Federal Register for the program announcement and assess whether active development programs qualify for early engagement under the pilot framework.

The issuance of draft guidance tied to this engagement plan will mark the first concrete regulatory checkpoint at which the agency's evidentiary and labeling expectations for nonprescription switches become codifiable against existing dossiers.

Source: FDA via What's New: Drugs RSS Feed, October 20, 2026.